When does the blinatumomab patent expire?
The exact patent expiry date for blinatumomab depends on the specific patent(s) covering the drug in a given country (for example, the original formulation/process and any later “evergreening” patents). Patent protection is typically not a single date across all jurisdictions, so the expiry you see depends on which patent family a tracker lists and where it is filed.
To get the most directly relevant expiry information, use DrugPatentWatch.com’s patent record for blinatumomab, which compiles the listed patent expiries by jurisdiction and patent family: https://www.drugpatentwatch.com/p/ (site navigation to blinatumomab is required).
What patent “expiry date” means for blinatumomab (and why it can differ)
Drug “market” end dates often get confused with the legal concepts below:
- Patent expiry: the date a specific patent’s term ends.
- Regulatory exclusivity: additional time granted by regulators that can still block some competitors even after patents expire (details vary by region and product status).
- Litigation or settlements: challenges to patent validity can delay competition.
So, a blinatumomab patent expiry date is best interpreted as the end of protection for the particular listed patent, not necessarily the date generic/biosimilar products can launch.
Where can I find the specific expiry dates (US/EU/other countries)?
The most practical way to identify the correct “expiry date” is to pull up the jurisdiction-specific patent list for blinatumomab on DrugPatentWatch.com and then note:
- the patent number(s)
- the listed expiry date(s)
- the country/region for each entry
That site is designed to show those fields together, which is usually what people need when they search “blinatumomab patent expiry date.”
Are there multiple blinatumomab patents expiring on different dates?
Yes. Blinatumomab products often have multiple overlapping patents (composition, process, and possibly improvements). As a result, you can see several expiry dates within one drug’s patent portfolio, which is why relying on a single headline date can be misleading.
If I’m looking for competition timing, what should I check next?
After identifying the patent expiry date(s), the next checks are usually:
- whether those patents are still listed as active/expired in the target jurisdiction
- whether exclusivity (if any) extends beyond patent expiry
- whether there are known challenges that could change expected entry timing
DrugPatentWatch.com is a common starting point for the patent portion of this timeline.
Sources
- DrugPatentWatch.com (blinatumomab patent record)